For decades, we’ve been talking about important reforms to the U.S. healthcare system as a whole – including aligning price and value of all healthcare services (not just prescription drugs) and reducing patient out-of-pocket costs – with very few conc…
SARS-CoV-2 is a master of deception, capable of evading and suppressing our immune system in multiple ways. New research describes a previously unknown strategy: mimicry of histone proteins, which help regulate gene expression.
A new Swiss study has discovered that certain levels of acidity can inactivate different viruses, providing a new tool to control airborne transmission.
Lecanemab’s PDUFA date for its potential accelerated approval is January 6th. The product could launch after its FDA approval. Now the discussion turns to what price it will be launched at, and whether it will eventually be reimbursed by CMS, the predo…
Mark Cuban’s Cost Plus Drug Company is making waves again, as it steadily raises its profile in the generic drugs sector. With more than 1.5 million customers, the company is fast becoming a major disruptor in generic drug pricing.
The biggest health story from 2022 isn’t Covid-19. It isn’t RSV or influenza, either. It isn’t cancer, diabetes, or cardiovascular disease. It’s something that encompasses all these diseases and much more. It’s the troubling decline in U.S. life expect…
It’s that time of year again. New year’s resolutions and predictions for the upcoming year. Here, I give some predictions for the economy, public health, and the biopharmaceutical sector.
The CAR T cell therapy targeted two different proteins on leukemia cells and 99% of children responded to the treatment.
The U.K. government is at least a decade behind target to have under 5% of U.K. adults smoking by 2030.
A study published in Science demonstrates how synthetic gene circuits could improve CAR T therapy’s precision and efficacy.
